Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging

NCT05687864 | Unknown Phase 1

• 1 other identifier: DJTCSCYHT-I-04
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Polysaccharide super paramagnetic ferric oxide injection is an iron supplement developed for patients with iron deficiency anemia. Due to its characteristics, it has the potential to be a contrast agent. The DJTCSCYHT-I-04 study is a single-center, multiple-strength and single-dose phase I clinical study on cardiovascular MRI in patients with chronic kidney disease, aiming to investigate the effects and safety of multi-strength, single-dose at different time points, and to provide reference for clinical diagnosis and MRI enhancement.

Conditions

Magnetic Resonance Imaging; Chronic Kidney Diseases

Outcome Measures

Primary Outcomes (6)

• Signal-to-Noise Ratio (SNR)

  On the basis of vascular segments, the signal-to-noise ratio at different doses and time points was calculated by magnetic resonance imaging.

  Before administration, 5minutes, 24 hours, 48 hours after administration

• Contrast to noise ratio (CNR)

  On the basis of vascular segments, the Contrast to noise ratio at different doses and time points was calculated by magnetic resonance imaging.

  Before administration, 5minutes, 24 hours, 48 hours after administration

• Image quality score before administration

  On the basis of vascular segments, the image quality of different doses at different time points was evaluated by magnetic resonance imaging. 4 points: the blood vessel edge is clear and sharp, without image artifacts, which can support the judgment of high confidence; 3 points: The overall portrayal effect of blood vessels was satisfactory, the anatomical structure of blood vessels was clear enough to meet the requirements of disease diagnosis, and there were mild image artifacts; 2 points: Blood vessels were visible, but only the local structure size or blood vessel patency could be judged, with moderate image artifacts; 1 point: poor image quality, serious image artifacts, unable to distinguish blood vessels and other tissues, unable to evaluate.

  Before administration

• Image quality score at 5 minutes

  On the basis of vascular segments, the image quality of different doses at different time points was evaluated by magnetic resonance imaging. 4 points: the blood vessel edge is clear and sharp, without image artifacts, which can support the judgment of high confidence; 3 points: The overall portrayal effect of blood vessels was satisfactory, the anatomical structure of blood vessels was clear enough to meet the requirements of disease diagnosis, and there were mild image artifacts; 2 points: Blood vessels were visible, but only the local structure size or blood vessel patency could be judged, with moderate image artifacts; 1 point: poor image quality, serious image artifacts, unable to distinguish blood vessels and other tissues, unable to evaluate.

  5 minutes after administration

• Image quality score at 24 hours

  On the basis of vascular segments, the image quality of different doses at different time points was evaluated by magnetic resonance imaging. 4 points: the blood vessel edge is clear and sharp, without image artifacts, which can support the judgment of high confidence; 3 points: The overall portrayal effect of blood vessels was satisfactory, the anatomical structure of blood vessels was clear enough to meet the requirements of disease diagnosis, and there were mild image artifacts; 2 points: Blood vessels were visible, but only the local structure size or blood vessel patency could be judged, with moderate image artifacts; 1 point: poor image quality, serious image artifacts, unable to distinguish blood vessels and other tissues, unable to evaluate.

  24 hours after administration

• Image quality score at 48 hours

  On the basis of vascular segments, the image quality of different doses at different time points was evaluated by magnetic resonance imaging. 4 points: the blood vessel edge is clear and sharp, without image artifacts, which can support the judgment of high confidence; 3 points: The overall portrayal effect of blood vessels was satisfactory, the anatomical structure of blood vessels was clear enough to meet the requirements of disease diagnosis, and there were mild image artifacts; 2 points: Blood vessels were visible, but only the local structure size or blood vessel patency could be judged, with moderate image artifacts; 1 point: poor image quality, serious image artifacts, unable to distinguish blood vessels and other tissues, unable to evaluate.

  48 hours after administration

Secondary Outcomes (5)

• T2* value of Liver

  Before administration, and day 28, day 60, day 90 after administration

• R2 value of Liver

  Before administration, and day 28, day 60, day 90 after administration

• Magnetic sensitivity of brain tissue

  Before administration, and day 28, day 60, day 90 after administration

• Incidence of adverse events

  From the enrollment of the subjects to 90 days after administration

• Incidence of severe adverse events

  From the enrollment of the subjects to 90 days after administration

Study Arms (1)

Polysaccharide superparamagnetic ferric oxide injection

EXPERIMENTAL

Participants will receive one single dose of 1mg/kg or 2mg/kg or 3mg/kg or 4mg/kg or 5mg/kg of Polysaccharide superparamagnetic ferric oxide injection on Day 1.

Diagnostic Test: Polysaccharide superparamagnetic ferric oxide injection

Interventions

Polysaccharide superparamagnetic ferric oxide injection DIAGNOSTIC_TEST

The polysaccharide superparamagnetic ferric oxide injection is a clinical diagnostic reagent

Polysaccharide superparamagnetic ferric oxide injection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subjects voluntarily joined the study, signed the informed consent, and the compliance was good.;
• Age: ≥18 years old (at the time of signing the informed consent), gender is not limited;
• Patients diagnosed with Chronic Kidney Disease (CKD, 2012 KDIGO Guidelines);
• Eastern Cooperative Oncology Group (ECOG) score 0\~1; Expected survival ≥3 months;
• Serum ferritin ≤ 1000μg/L and transferrin saturation ≤ 50%;
• The major organs function are good and meet the following criteria:
• blood routine examination:
• Hemoglobin ≥ 90g/L
• Neutrophil count (NEUT) ≥1.5×109/L;
• Platelet count (PLT) ≥ 75×109/L;
• Biochemical examination should meet the following standards:
• Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
• Alanine transferase (ALT), aspartate transferase (AST) and gamma glutamyltransferase (gamma-GGT) ≤ 3ULN;
• Left ventricular ejection fraction (LVEF) ≥50%.
• Women of reproductive age should agree to use effective birth control during the study period and for 6 months after the study, and have a negative serum-pregnancy test within 7 days prior to study enrollment; Men should agree that effective birth control must be used during the study period and for six months after the end of the study period.

You may not qualify if:

• patients with other malignancies treated with a single operation achieved continuous 5-year disease-free survival (DFS);
• Cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)\];
• The disease was stable as assessed by the investigators, and the concomitant drugs did not affect medication during the trial and follow-up period.
• Subjects with any severe and/or uncontrolled medical conditions, including:
• Poorly controlled hypertension (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100 mmHg) or poorly controlled hypotension (systolic blood pressure \<90mmHg or diastolic blood pressure \<60 mmHg);
• Have ≥ grade 2 myocardial ischemia or myocardial infarction and/or severe or malignant arrhythmias \[including QTc ≥450ms in men, QTc ≥470ms in women\] and/or ≥ grade 2 congestive heart failure \[New York Heart Association (NYHA)\];
• Active infection (≥NCI, CTC AE 5.0, Grade 2);
• Viral hepatitis, syphilis, HIV and other infectious diseases;
• A history of immunodeficiency, including acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
• People who have epilepsy and require treatment.
• Research and treatment related:
• Patients with iron deficiency anemia;
• Subjects who are allergic to intravenous iron preparations, the investigational drug or any of its components, or two or more types of drugs;
• Subjects who plan to undergo magnetic resonance imaging during the study period and during follow-up.
• Participants who have participated in other clinical trials of drugs or medical device within 28 days before the start of the study treatment;

Sponsors & Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

Beijing Chaoyang Hospital, Capital Medical University

Beijing, Beijing Municipality, 100020, China

RECRUITING

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2023
• First Posted: January 18, 2023
• Study Start: June 17, 2023
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: June 27, 2023

Record last verified: 2022-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)